We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 107% below its sector, cheaper than its peers on earnings.
OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's extensive product pipeline features numerous advanced treatment candidates. These include Adagloxad Simolenin (OBI-822), an active immunity drug for breast cancer designed to stimulate antibody production against the tumor carbohydrate antigen Globo H; OBI-833, an immunity-boosting anti-cancer agent targeting lung cancer; OBI-866 SSEA-4, another active immune-oncology medication; and OBI-888, a passive immunotherapy monoclonal antibody also developed to confront Globo H. Additionally, their portfolio contains OBI-999, an antibody-drug conjugate; OBI-3424, a small-molecule chemotherapy prodrug; OBI-858, a botulinum toxin; and other investigational drugs such as OBI-898 and OBI-998. Founded in 2002, the enterprise is headquartered in Taipei, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 4174.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
